Protection and Virus Shedding of Falcons Vaccinated against Highly Pathogenic Avian Influenza A Virus (H5N1)
Michael Lierz* , Hafez M. Hafez*, Robert Klopfleisch†, Dörte Lüschow*, Christine Prusas*, Jens P. Teifke†, Miriam Rudolf†, Christian Grund†, Donata Kalthoff†, Thomas Mettenleiter†, Martin Beer†, and Timm Harder†
Author affiliations: *Freie Universität, Berlin, Germany; †Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany;
Figure 1. Titers (log2) of hemagglutination-inhibiting antibodies of 5 vaccinated Gyr-Saker hybrid falcons before and 11 days after challenge with 106.0 50% egg infectious doses of the highly pathogenic avian influenza strain A/Cygnus cygnus/Germany/R65/06 (H5N1), tested against antigen of the challenge virus and the low pathogenicity avian influenza vaccine strain A/duck/Potsdam/1402/86 (H5N2). Open circle, individual outlier.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.